Biocryst Pharmaceuticals (BCRX) Short term Debt (2016 - 2026)

Biocryst Pharmaceuticals' Short term Debt history runs 9 years deep, the most recent figure standing at $40.3 million for Q1 2026.

• Quarterly Short term Debt rose 17.53% year-over-year to $40.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.3 million (up 17.53% YoY) and the FY2025 annual result came in at $38.5 million, up 17.69% from the prior year.
• Short term Debt was $40.3 million for Q1 2026 at Biocryst Pharmaceuticals, up from $38.5 million in the prior quarter.
• Across five years, Short term Debt topped out at $40.3 million in Q1 2026 and bottomed at $23.6 million in Q4 2023.
• A 4-year average of $33.1 million and a median of $33.7 million in 2024 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt soared 38.66% — and 2025, when it gained 14.2%.
• Biocryst Pharmaceuticals' Short term Debt stood at $23.6 million in 2023, then surged by 38.66% to $32.7 million in 2024, then advanced by 17.69% to $38.5 million in 2025, then increased by 4.84% to $40.3 million in 2026.
• Business Quant data shows BCRX's Short term Debt at $40.3 million in Q1 2026, $38.5 million in Q4 2025, and $37.7 million in Q3 2025.